Cargando…

Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment

BACKGROUND: Cisplatin plus pemetrexed combination therapy is considered the standard treatment for patients with advanced, non-squamous, non-small-cell lung cancer (NSCLC). However, advanced NSCLC has a 5-year survival rate of below 10%, which is mainly due to therapy resistance. We previously showe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yanyun, Dorn, Patrick, Liu, Shengchen, Deng, Haibin, Hall, Sean R. R., Peng, Ren-Wang, Schmid, Ralph A., Marti, Thomas M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883680/ https://www.ncbi.nlm.nih.gov/pubmed/31798346 http://dx.doi.org/10.1186/s12935-019-1037-1

Ejemplares similares

Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells
por: Dorn, Patrick, et al.
Publicado: (2016)

The effect of tetrandrine combined with cisplatin on proliferation and apoptosis of A549/DDP cells and A549 cells
por: Ye, Ling-Yun, et al.
Publicado: (2017)

Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT
por: Tièche, Colin Charles, et al.
Publicado: (2016)

MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin
por: Li, Weili, et al.
Publicado: (2016)

NMR studies of the relationship between the changes of membrane lipids and the cisplatin-resistance of A549/DDP cells
por: Huang, Zhenhua, et al.
Publicado: (2003)

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
por: Qin, Yiyang, et al.
Publicado: (2017)

Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells
por: Conroy, Lindsey R., et al.
Publicado: (2020)

Effect of DNA methylation inhibitor on RASSF1A genes expression in non-small cell lung cancer cell line A549 and A549DDP
por: Mengxi, Duan, et al.
Publicado: (2013)

Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells
por: Shang, Bin, et al.
Publicado: (2017)

Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549()
por: Tièche, Colin Charles, et al.
Publicado: (2018)

Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
por: Chen, Jihui, et al.
Publicado: (2021)

Responses of genes involved in cell cycle control to diverse DNA damaging chemicals in human lung adenocarcinoma A549 cells
por: Zhu, Huijun, et al.
Publicado: (2005)

Hyperhydration with cisplatin does not influence pemetrexed exposure
por: de Rouw, Nikki, et al.
Publicado: (2021)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
por: Jia, Bo, et al.
Publicado: (2020)

Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT
por: Qi, Yuxin, et al.
Publicado: (2021)

Vγ9Vδ2 T cells strengthen cisplatin inhibition activity against breast cancer MDA-MB-231 cells by disrupting mitochondrial function and cell ultrastructure
por: Huang, Xin, et al.
Publicado: (2021)

Paclitaxel and the dietary flavonoid fisetin: a synergistic combination that induces mitotic catastrophe and autophagic cell death in A549 non-small cell lung cancer cells
por: Klimaszewska-Wisniewska, Anna, et al.
Publicado: (2016)

SOX17 increases the cisplatin sensitivity of an endometrial cancer cell line
por: Zhang, Yongli, et al.
Publicado: (2016)

Dimethylsulfoxide excerbates cisplatin-induced cytotoxicity in Ehrlich ascites carcinoma cells
por: Osman, Abdel-Moneim M., et al.
Publicado: (2015)

Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: Does the response involve senescence? The possible role of vimentin
por: Litwiniec, Anna, et al.
Publicado: (2013)

Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)
por: Gao, Yanyun, et al.
Publicado: (2021)

Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness
por: Schmidtova, Silvia, et al.
Publicado: (2020)

Hypoxia-induced Tie1 drives stemness and cisplatin resistance in non-small cell lung carcinoma cells
por: Li, Chaojie, et al.
Publicado: (2021)

Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
por: Zhu, Jian, et al.
Publicado: (2019)

Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells
por: Horibe, Sayo, et al.
Publicado: (2022)

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
por: Garrido, Pilar, et al.
Publicado: (2017)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity
por: Freeburg, Elizabeth M, et al.
Publicado: (2009)

Quercetin-induced inhibition and synergistic activity with cisplatin – a chemotherapeutic strategy for nasopharyngeal carcinoma cells
por: Daker, Maelinda, et al.
Publicado: (2012)

High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase
por: Kuo, Wei-Ting, et al.
Publicado: (2017)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells
por: Wang, Jing, et al.
Publicado: (2019)

Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma
por: Karatkevich, Darya, et al.
Publicado: (2022)

Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein
por: Choi, Cheol-Hee, et al.
Publicado: (2004)

Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin
por: Kapperman, Heather E., et al.
Publicado: (2018)

CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells
por: Zamagni, Alice, et al.
Publicado: (2020)

Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression
por: Calogero, Antonella, et al.
Publicado: (2011)

Interferon-β Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells
por: Li, Quanhai, et al.
Publicado: (2013)

Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc
por: Luo, Haitao, et al.
Publicado: (2010)

Synergistic anticancer effect of combined crocetin and cisplatin on KYSE-150 cells via p53/p21 pathway
por: Li, Sheng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i2a80q436rdaqn1o0b968acuqo